

REFERENCES

- Webb C. Checklist of dicotyledons naturalised in New Zealand. *NZ J Bot* 1980;18:463-72 (<http://www.tandfonline.com/toc/tnzb20/18/4#.VHzQ6snDXM0>)
- Godley E. Introducing Kowhai. Styx report. Christchurch, New Zealand: Landcare Research, 2006.
- Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an $\alpha 4\beta 2$ nicotinic receptor partial agonist for smoking cessation. *J Med Chem* 2005;48:3474-7.
- Jeong S-H, Newcombe D, Sheridan J, Tingle M. Pharmacokinetics of cytisine, an $\alpha 4\beta 2$ nicotinic receptor partial agonist, in healthy smokers following a single dose. *Drug Test Anal* 2014 September 17 (Epub ahead of print).
- Tutka P, Zatoński W. Cytisine for the treatment of nicotine addiction: from a molecule to therapeutic efficacy. *Pharmacol Rep* 2006;58:777-98.
- Etter JF. Cytisine for smoking cessation: a literature review and a meta-analysis. *Arch Intern Med* 2006;166:1553-9.
- Hajek P, McRobbie H, Myers K. Efficacy of cytisine in helping smokers quit: systematic review and meta-analysis. *Thorax* 2013;68:1037-42.
- Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. *Cochrane Database Syst Rev* 2011;2:CD006103.
- McRobbie H, Hajek P, Bullen C, Feigin V. Rapid review of non-NHS treatments for smoking cessation. London: National Institute of Health and Care Excellence, 2006 (<http://www.nice.org.uk/guidance/ph10/resources/evidence-review-nonnhs-treatments2>).
- Aveyard P, West R. Cytisine and the failure to market and regulate for human health. *Thorax* 2013;68:989.
- Prochaska JJ, Das S, Benowitz NL. Cytisine, the world's oldest smoking cessation aid. *BMJ* 2013;347:f5198.
- Stapleton JA. The case for licensing cytosine now for smoking cessation is overwhelming. *BMJ* 2013;347:f5736.
- Stapleton JA, West R. A direct method and ICER tables for the estimation of the cost-effectiveness of smoking cessation interventions in general populations: application to a new cytisine trial and other examples. *Nicotine Tob Res* 2012;14:463-71.
- Walker N, Howe C, Bullen C, et al. Study protocol for a non-inferiority trial of cytisine versus nicotine replacement therapy in people motivated to stop smoking. *BMC Public Health* 2011;11:880.
- Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. *Br J Addict* 1991;86:1119-27.
- Fagerström K. Determinants of tobacco use and renaming the FTND to the Fagerstrom Test for Cigarette Dependence. *Nicotine Tob Res* 2012;14:75-8.
- New Zealand smoking cessation guidelines. Wellington, New Zealand: Ministry of Health; 2007.
- West R, Hajek P. Evaluation of the mood and physical symptoms scale (MPSS) to assess cigarette withdrawal. *Psychopharmacology (Berl)* 2004;177:195-9.
- Bush K, Kivlahan D, McDonell M, Fihn S, Bradley K. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinkers. *Arch Intern Med* 1998;158:1789-95.
- Cappelleri JC, Bushmakin AG, Baker CL, Merikle E, Olufade AO, Gilbert DG. Confirmatory factor analyses and reliability of the modified cigarette evaluation questionnaire. *Addict Behav* 2007;32:912-23.
- West R, Hajek P, Stead L, Stapleton J. Outcome criteria in smoking cessation trials: proposal for a common standard. *Addiction* 2005;100:299-303.
- Stead L, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. *Cochrane Database of Systematic Reviews*. *Cochrane Libr* 2008;3:CD000146.
- Cepeda-Benito A, Reynoso JT, Erath S. Meta-analysis of the efficacy of nicotine replacement therapy for smoking cessation: differences between men and women. *J Consult Clin Psychol* 2004;72:712-22.
- Perkins KA, Scott J. Sex differences in long-term smoking cessation rates due to nicotine patch. *Nicotine Tob Res* 2008;10:1245-50.
- West R, Zatonski W, Cedzynska M, et al. Placebo-controlled trial of cytisine for smoking cessation. *N Engl J Med* 2011;365:1193-200.
- Li J, Grigg M. Changes in characteristics of New Zealand Quitline callers between 2001 and 2005. *N Z Med J* 2007;120:U2584.
- Bullen C, Howe C, Grigg M, et al. Recruitment into a cessation trial via the New Zealand Quitline: many benefits, few limitations. *J Smoking Cessation* 2008;3:30-4.
- Li J. How do Quitline callers compare to the New Zealand smoking population? Wellington, New Zealand: The Quit Group, 2007.
- Tobacco use in New Zealand: key findings from the 2009 New Zealand Tobacco Use Survey. Wellington, New Zealand: Ministry of Health, 2010 (<http://www.health.govt.nz/publication/tobacco-use-new-zealand-key-findings-2009-nz-tobacco-use-survey>).
- Bullen C, Howe C, Lin RB, et al. Pre-cessation nicotine replacement therapy: pragmatic randomized trial. *Addiction* 2010;105:1474-83.
- Walker N, Howe C, Bullen C, et al. Does improved access and greater choice of nicotine replacement therapy affect smoking cessation success? Findings

from a randomized controlled trial. *Addiction* 2011;106:1176-85.

32. Walker N, Howe C, Bullen C, et al. The combined effect of very low nicotine content cigarettes, used as an adjunct to usual Quitline care (nicotine replacement therapy and behavioural support), on

smoking cessation: a randomized controlled trial. *Addiction* 2012;107:1857-67.

33. Borland R, Segal CJ, Livingston PM, Owen N. The effectiveness of callback counselling for smoking cessation: a randomized trial. *Addiction* 2001;96:881-9.

34. Aubin H-J, Bobak A, Britton JR, et al.

Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. *Thorax* 2008;63:717-24.

Copyright © 2014 Massachusetts Medical Society.